RxDoctor Payments Data

Andrea Hakimi, DO

Neurology · Greenville, SCNPI 1679681308

Payments from drug & device makers

$1,550in general payments, 2019–2025

Across 35 payments — averaging $44.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$1K
  • Neuropace, Inc.$131
  • Medtronic$57
  • AbbVie$42
  • Neurocrine Biosciences, Inc.$20
  • Upsher-smith Laboratories LLC$19
  • plus $18 from 1 others

What the payments were for

  • Food & beverage$1,550100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,550 in reported general payments places this provider in the 55th percentile of 270 neurology providers in South Carolina.

See all neurology providers in South Carolina

Medicare billing

Part B allowed, 2024
$45,622
Medicare patients
280
Services billed
387

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate67$81,424
FycompaPerampanel36$65,117
VimpatLacosamide42$56,639
EpidiolexCannabidiol (Cbd)12$54,711
LamictalLamotrigine34$47,140
Lacosamide295$34,189
NayzilamMidazolam30$29,639
TopamaxTopiramate14$29,509
OnfiClobazam11$25,623
BriviactBrivaracetam21$24,776
Levetiracetam390$21,288
Clobazam113$19,390
Felbamate22$10,609
TegretolCarbamazepine18$9,806
EprontiaTopiramate11$7,034

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Upsher-smith Laboratories LLCTopiramate$19$3,970130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 270 neurology providers in South Carolina.

Other neurology in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →